Gene, Cell and Tissue

Published by: Neoscriber Demo Publisher
Crossmark

Targeted Delivery of Therapeutic Agents by Smart Nanocarrier for Treatment of Parkinson’s Disease: A Novel Brain Targeting Approach

Fatemeh Moradi 1 , Houman Parsaie 1 , 2 and Enam Alhagh Charkhat Gorgich ORCID 1 , 2 , 3 , *
Authors Information
1 Department of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
2 Students’ Scientific Association of Anatomical Sciences, School of Medicine, Iran University of Medical Sciences, Tehran, Iran
3 Department of Histology, School of Medicine, Zahedan University of Medical Sciences, Zahedan, Iran
Article information
  • Gene, Cell and Tissue: 6 (2); e91213
  • Published Online: March 13, 2019
  • Article Type: Letter
  • Received: March 3, 2019
  • Revised: March 7, 2019
  • Accepted: March 9, 2019
  • DOI: 10.5812/gct.91213

To Cite: Moradi F, Parsaie H, Charkhat Gorgich E A. Targeted Delivery of Therapeutic Agents by Smart Nanocarrier for Treatment of Parkinson’s Disease: A Novel Brain Targeting Approach, Gene Cell Tissue. Online ahead of Print ; 6(2):e91213. doi: 10.5812/gct.91213.

Copyright © 2019, Gene, Cell and Tissue. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
Footnotes
References
  • 1. Tolosa E, Wenning G, Poewe W. The diagnosis of parkinson's disease. Lancet Neurol. 2006;5(1):75-86. doi: 10.1016/S1474-4422(05)70285-4.
  • 2. Heidari Z, Moghtaderi A, Mahmoudzadeh-Sagheb H, Gorgich EA. Stereological evaluation of the brains in patients with parkinson’s disease compared to controls. Rev Romana Med Lab. 2017;25(3):265-74. doi: 10.1515/rrlm-2017-0010.
  • 3. Huot P, Johnston TH, Koprich JB, Fox SH, Brotchie JM. The pharmacology of L-DOPA-induced dyskinesia in Parkinson's disease. Pharmacol Rev. 2013;65(1):171-222. doi: 10.1124/pr.111.005678. [PubMed: 23319549].
  • 4. Li Y, Zhou Y, Qi B, Gong T, Sun X, Fu Y, et al. Brain-specific delivery of dopamine mediated by n,n-dimethyl amino group for the treatment of Parkinson's disease. Mol Pharm. 2014;11(9):3174-85. doi: 10.1021/mp500352p. [PubMed: 25072272].
  • 5. Qu M, Lin Q, He S, Wang L, Fu Y, Zhang Z, et al. A brain targeting functionalized liposomes of the dopamine derivative N-3,4-bis(pivaloyloxy)-dopamine for treatment of Parkinson's disease. J Control Release. 2018;277:173-82. doi: 10.1016/j.jconrel.2018.03.019. [PubMed: 29588159].
  • 6. Belfiore L, Saunders DN, Ranson M, Thurecht KJ, Storm G, Vine KL. Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: Challenges and opportunities. J Control Release. 2018;277:1-13. doi: 10.1016/j.jconrel.2018.02.040. [PubMed: 29501721].
  • 7. Vlieghe P, Khrestchatisky M. Medicinal chemistry based approaches and nanotechnology-based systems to improve CNS drug targeting and delivery. Med Res Rev. 2013;33(3):457-516. doi: 10.1002/med.21252. [PubMed: 22434495].
  • 8. Sanchez-Moreno P, Ortega-Vinuesa JL, Peula-Garcia JM, Marchal JA, Boulaiz H. Smart drug-delivery systems for cancer nanotherapy. Curr Drug Targets. 2018;19(4):339-59. doi: 10.2174/1389450117666160527142544. [PubMed: 27231107].
  • 9. Liu Y, Li J, Shao K, Huang R, Ye L, Lou J, et al. A leptin derived 30-amino-acid peptide modified pegylated poly-L-lysine dendrigraft for brain targeted gene delivery. Biomaterials. 2010;31(19):5246-57. doi: 10.1016/j.biomaterials.2010.03.011. [PubMed: 20382424].
  • 10. Kumar P, Wu H, McBride JL, Jung KE, Kim MH, Davidson BL, et al. Transvascular delivery of small interfering RNA to the central nervous system. Nature. 2007;448(7149):39-43. doi: 10.1038/nature05901. [PubMed: 17572664].
  • 11. Liu Y, Li D, Liu Z, Zhou Y, Chu D, Li X, et al. Targeted exosome-mediated delivery of opioid receptor Mu siRNA for the treatment of morphine relapse. Sci Rep. 2015;5:17543. doi: 10.1038/srep17543. [PubMed: 26633001]. [PubMed Central: PMC4668387].
  • 12. Lam FC, Morton SW, Wyckoff J, Vu Han TL, Hwang MK, Maffa A, et al. Enhanced efficacy of combined temozolomide and bromodomain inhibitor therapy for gliomas using targeted nanoparticles. Nat Commun. 2018;9(1):1991. doi: 10.1038/s41467-018-04315-4. [PubMed: 29777137]. [PubMed Central: PMC5959860].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments